Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atamparib (Primary)
  • Indications Advanced breast cancer; Lung cancer; Lymphoma; Mantle-cell lymphoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Ribon Therapeutics

    • Most Recent Events

    • 19 Apr 2023 Results As of 2 July 2022, (n= 31)presented at the 114th Annual Meeting of the American Association for Cancer Research
    • 27 Mar 2023 Planned End Date changed from 31 Jan 2023 to 31 Jul 2023.
    • 27 Mar 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top